Cargando…

Societal preferences for adjuvant melanoma health states: UK and Australia

BACKGROUND: No studies have measured preference-based utility weights for specific toxicities and outcomes associated with approved and investigational adjuvant treatments for patients with resected high-risk melanoma. METHODS: A cross-sectional study was conducted in the United Kingdom and Australi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Middleton, Mark R., Atkins, Michael B., Amos, Kaitlan, Wang, Peter Feng, Kotapati, Srividya, Sabater, Javier, Beusterien, Kathleen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5646133/ https://www.ncbi.nlm.nih.gov/pubmed/29041898 http://dx.doi.org/10.1186/s12885-017-3673-y

Ejemplares similares

Societal preference values for advanced melanoma health states in the United Kingdom and Australia
por: Beusterien, K M, et al.
Publicado: (2009)

Comparative efficacy and safety of adjuvant nivolumab versus other treatments in adults with resected melanoma: a systematic literature review and network meta-analysis
por: Toor, Kabirraaj, et al.
Publicado: (2021)

Retrospective analysis of drug utilization, health care resource use, and costs associated with IFN therapy for adjuvant treatment of malignant melanoma
por: Zhang, Ying, et al.
Publicado: (2015)

Assessment of the societal and individual preferences for fertility treatment in Australia: study protocol for stated preference discrete choice experiments
por: Botha, Willings, et al.
Publicado: (2018)

Japanese patient preferences regarding intermediate to advanced hepatocellular carcinoma treatments
por: Chiba, Tetsuhiro, et al.
Publicado: (2019)

Real‐World nivolumab dosing patterns and safety outcomes in patients receiving adjuvant therapy for melanoma
por: Samlowski, Wolfram, et al.
Publicado: (2022)

Modelling Survival of Patients Treated with Adjuvant Nivolumab Who Have Melanoma with Lymph Node Involvement or Metastatic Disease After Complete Resection
por: Batteson, Rachael, et al.
Publicado: (2019)

Patient Preferences for Adjuvant Treatment in Muscle-Invasive Urothelial Carcinoma: A Multi-Country Discrete Choice Experiment
por: King-Concialdi, Kristen, et al.
Publicado: (2023)

Cost-Utility of Nivolumab Plus Ipilimumab in First-Line Treatment of Advanced Melanoma in the United States: An Analysis Using Long-Term Overall Survival Data from Checkmate 067
por: Baker, Timothy, et al.
Publicado: (2022)

Adjuvant interferon in the treatment of melanoma
por: Middleton, M R
Publicado: (1999)

Taxonomic bias in biodiversity data and societal preferences
por: Troudet, Julien, et al.
Publicado: (2017)

Patient preferences for chemotherapies used in breast cancer
por: Beusterien, Kathleen, et al.
Publicado: (2012)

Patient, Oncologist, and Payer Preferences for Adjuvant Endocrine Therapy and CDK4/6 Inhibitor Regimens in Early-Stage Breast Cancer: A Discrete Choice Experiment
por: Beusterien, Kathleen, et al.
Publicado: (2021)

Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanoma
por: Potluri, Ravi, et al.
Publicado: (2019)

Real‐world treatment practice in patients with advanced melanoma in the era before ipilimumab: results from the IMAGE study
por: Middleton, Mark R., et al.
Publicado: (2016)

Adjuvant interferon in the treatment of melanoma – reply
por: Middleton, M R
Publicado: (2000)

Patient and Neurologist Preferences in the United States for Relapsing-Remitting Multiple Sclerosis Treatments: Findings from a Discrete Choice Experiment
por: Kumar, Jinender, et al.
Publicado: (2021)

Patient preferences in the treatment of diabetic retinopathy
por: Wirostko, Barbara, et al.
Publicado: (2011)

Adjuvant interferon in melanoma – a resurrection?
por: Middleton, M R, et al.
Publicado: (2001)

Assessing societal and offender perspectives on the value of offender healthcare: a stated preference research protocol
por: Settumba, Stella Nalukwago, et al.
Publicado: (2019)

Personal and societal costs of multiple sclerosis in the UK: A population-based MS Registry study
por: Nicholas, Richard S, et al.
Publicado: (2020)

Code des sociétés: dispositions générales, sociétés civiles, sociétés commerciales, sociétés cotées en bourse, sociétés particulières
por: France
Publicado: (1999)

How does framing influence preference for multiple solutions to societal problems?
por: Wu, James Shyan-Tau, et al.
Publicado: (2023)

Sociétés animales société humaine
por: Chauchard, Paul, 1912-2003
Publicado: (1956)

Patient Preferences in Adjuvant and Palliative Treatment of Advanced Melanoma: A Discrete Choice Experiment
por: WEILANDT, Juliane, et al.
Publicado: (2020)

Comparison of Modes of Administration and Alternative Formats for Eliciting Societal Preferences for Burden of Illness
por: Rowen, Donna, et al.
Publicado: (2015)

Resource allocation in NHS dentistry: recognition of societal preferences (RAINDROP): study protocol
por: Vernazza, Christopher R., et al.
Publicado: (2018)

Societal preferences for the treatment of impulsive-violent offenders: a discrete choice experiment
por: Settumba, Stella, et al.
Publicado: (2021)

Preferences of German and Swiss melanoma patients for toxicities versus melanoma recurrence during adjuvant treatment (GERMELATOX-A-trial)
por: Kähler, Katharina C., et al.
Publicado: (2023)

Estimated societal costs of stroke in the UK based on a discrete event simulation
por: Patel, Anita, et al.
Publicado: (2020)

Using a stated preference discrete choice experiment to assess societal value from the perspective of patients with rare diseases in Italy
por: López-Bastida, Julio, et al.
Publicado: (2019)

Preferences for Adjuvant Immunotherapy in Adults with Resected Stage III Melanoma—A Discrete Choice Experiment
por: Livingstone, Ann, et al.
Publicado: (2023)

Societal preferences for standard health insurance coverage in the Netherlands: a cross-sectional study
por: van der Wulp, Ineke, et al.
Publicado: (2012)

Societal preferences for funding orphan drugs in China: An application of the discrete choice experiment method
por: Tan, Shuoyuan, et al.
Publicado: (2022)

Valuation of Treatments for Rare Diseases: A Systematic Literature Review of Societal Preference Studies
por: Dabbous, Omar, et al.
Publicado: (2022)

Societal Preferences for Meningococcal B Vaccination in Children: A Discrete Choice Experiment in Spain
por: Martinón-Torres, Federico, et al.
Publicado: (2022)

The societal benefits of reducing six behavioural risk factors: an economic modelling study from Australia
por: Cadilhac, Dominique A, et al.
Publicado: (2011)

The economic and health burden of stroke among younger adults in Australia from a societal perspective
por: Tan, Elise, et al.
Publicado: (2022)

Recent developments in podiatric prescribing in the UK and Australia
por: Gilheany, Mark F, et al.
Publicado: (2009)

An update on adjuvant systemic therapies in melanoma
por: Samuel, Evangeline, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ccsqvfh6tc1r8ivtit1gfqe8ql